Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications

Diffuse large B-cell lymphoma (DLBCL) represents a group of tumors characterized by substantial heterogeneity in terms of their pathological and biological features, a causal factor of their varied clinical outcome. This variation has persisted despite the implementation of rituximab in treatment re...

Descripción completa

Detalles Bibliográficos
Autores principales: Papageorgiou, Sotirios G., Thomopoulos, Thomas P., Katagas, Ioannis, Bouchla, Anthi, Pappa, Vassiliki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150462/
https://www.ncbi.nlm.nih.gov/pubmed/34104369
http://dx.doi.org/10.1177/20406207211013987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150462/
https://www.ncbi.nlm.nih.gov/pubmed/34104369
http://dx.doi.org/10.1177/20406207211013987

Ejemplares similares